Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11808658 | 0.83 | GSK3B (0.55) | GSK3BENPP2GRM5CLK4TSHR | |
| SCHEMBL16502093 | 0.82 | GSK3B (0.53) | GSK3BENPP2GRM5CLK4TSHR | |
| SCHEMBL26049928 | 0.80 | CLK4 (0.49) | CLK4ALDH1A1 | |
| SCHEMBL9291447 | 0.80 | L3MBTL1 (0.36) | GSK3BTSHRALDH1A1MAPT | |
| SCHEMBL28879917 | 0.80 | GSK3B (0.51) | GSK3BENPP2GRM5CLK4TSHR | |
| SCHEMBL39137 | 0.80 | GSK3B (0.61) | GSK3BENPP2GRM5P4HBCLK1 | |
| SCHEMBL30239069 | 0.80 | GSK3B (0.61) | GSK3BENPP2GRM5P4HBCLK1 | |
| SCHEMBL14508038 | 0.80 | GSK3B (0.51) | GSK3BENPP2GRM5CLK4TSHR | |
| SCHEMBL14821933 | 0.80 | GSK3B (0.51) | GSK3BENPP2GRM5CLK4TSHR | |
| SCHEMBL28080869 | 0.80 | GSK3B (0.51) | GSK3BENPP2GRM5CLK4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027603-B1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2742040-B1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| EP-2742040-B1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2742040-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013024011-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| EP-2033963-B1 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2011-02-16 | — | — | EP | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| WO-2007060120-A1 | INDANYL-AND TETRAHYDRONAPHTYL-AMINO-THIOUREA COMPOUNDS FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | ZAPAQ, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| WO-2006110668-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | disclosed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CYP3A43, INSR, CYP2C19 | GSK3B 645/4885ENPP2 1860/4885GRM5 2739/4885 |
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | BACE1, BACE2, APP | GSK3B 178/4885ENPP2 284/4885GRM5 682/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | GSK3B 943/4885ENPP2 1485/4885GRM5 952/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | GSK3B 116/4885ENPP2 923/4885GRM5 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.